StemCell Therapy

Isabelle Amigues,1 Deepa Ramadurai,2 Jeffrey J Swigris3

1Division of Rheumatology, National Jewish Health, Denver, CO, USA; 2Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 3Division of Pulmonary, Critical Care and Sleep Medicine, Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA

Correspondence: Jeffrey J SwigrisNational Jewish Health, 1400 Jackson Street, Denver, CO 80206, USAEmail swigrisj@njc.org

Abstract: Rheumatoid arthritis (RA) is a common systemic autoimmune disease whose fibro-inflammatory manifestations may affect a number of tissues and organs, including the lungs. In fact, interstitial lung disease (ILD) is a leading cause of mortality among patients with RA. RA-related interstitial lung disease (RA-ILD) most often presents in an injury pattern called usual interstitial pneumonia (UIP), which portends a relatively worse prognosis than other less commonly occurring patterns of RA-ILD, like non-specific interstitial pneumonia (NSIP). Biomarkers from serum or bronchoalveolar lavage fluid could aid in the identification of patients at risk for RA-ILD, the detection of patients most likely to develop the UIP pattern of RA-ILD, and the prediction of disease behaviour over time. Notably, the use of highly sensitive serologic biomarkers, including rheumatoid factor (RF) and antibodies targeting cyclic citrullinated peptides, while somewhat specific for RA joint disease, have only limited utility as biomarkers for RA-ILD. Candidate biomarkers for RA-ILD include these and other autoantibodies as well as certain genes and molecules that hold promise as biomarkers in other forms of ILD. In this manuscript, we summarize the state of knowledge on biomarkers for the development and progression of RA-ILD.

Keywords: rheumatoid arthritis, interstitial lung disease, pulmonary fibrosis, usual interstitial pneumonia, biomarker, antibody

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the rest here:
Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-A | OARRR - Dove Medical Press

MANHATTAN, Kan. (WIBW) - To shake things up, the Arthritis Foundation Kansas Chapter, hosted a Halloween Hustle 5K run and 1 mile walk in Manhattan Saturday morning.

Participants were encouraged to come dressed up in costumes, and participate in the costume contest for chances to win prizes.

To continue the Halloween theme, there was also a Trick or Trot for the youth participants to receive candy on their trot around the pavilion.

After the Trick or Trot and costume contest participants headed outside for the 5K and 1 mile runs around Manhattans City Park.

Participants in the Halloween Hustle raised nearly thirty thousand dollars for Saturdays event to go towards the Arthritis Foundation.

We pride ourselves on being a research based organization, our goal is to find a cure, but we also provide programs and resources for people to help live their best life for people who are suffering now. Arthritis Foundation (KS Chapter), Development Manager, Lauren Hambleton says.

While this was the first Halloween themed event in Manhattan for the Arthritis Foundation, they plan to host the Halloween Hustle again in October 2020.

Follow this link:
'Halloween Hustle' for the Arthritis Foundation held in Manhattan - WIBW

For patients withrheumatoid arthritis (RA), rheumatoid factor (RF) and anti-citrullinatedprotein antibodies (ACPA) demonstrate different isotype patterns during diseasedevelopment, according to results published in Arthritis & Rheumatology.

The study included participants with RA (n=214) and matched control participants (n=210) from the Department of Defense Serum Repository. The researchers tested a mean of 3 pre-RA and 1 post-RA serum samples for RF and ACPA immunoglobulin (Ig) A, IgG, and IgM. They then evaluated the timing and trajectories of autoantibody elevations.

Compared withcontrol individuals, participants with RA had significant differences in RF-IgAlevels at a median of 14.2 years before diagnosis (P <.01).Differences in RF-IgG occurred at 5.0 years, and differences in RF-IgM levelsoccurred at 7.2 years (both P <.01).

Participants with RAhad significantly different levels of ACPA IgG at 17.9 years before RAdiagnosis compared with control individuals (P <.01). For ACPA-IgA,the difference occurred at 6.2 years, and for ACPA-IgM, it differed at 5.0years (both P <.01).

After RA diagnosis,the only autoantibody that had a significant positivity increase was ACPA-IgA(19% 0-2 years pre-RA vs. 39% >2 years post-RA, P =.04).

The resultsindicated that among participants with RA, all autoantibodies followed asimilar trajectory, with an early initial elevation, a period of stability, andan immediate increase pre-RA diagnosis.

The study includedseveral limitations. The researchers noted that the military cohort used in thestudy may have a more severe form of RA than other populations. In addition,delays in seeking treatment may mean that the actual time of synovitis onset isearlier than the date of diagnosis.

These findingshave implications for understanding the pathophysiology of disease development,the researchers wrote.

Disclosure: Severalstudy authors declared affiliations with the pharmaceutical industry. Pleasesee the original reference for a full list of authors disclosures.

Reference

Kelmenson LB, Wagner BD, McNair BK, et al. Timing of elevations of autoantibody isotypes in rheumatoid arthritis prior to disease diagnosis [published online August 29, 2019]. Arthritis Rheumatol. doi:10.1002/art.41091

More:
Variance in Isotype Patterns Before Rheumatoid Arthritis Diagnosis - Rheumatology Advisor

PETACH TIKVA, Israel--(BUSINESS WIRE)--

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases and Gebro Pharma, a European mid-size Pharmaceutical company announced today it is holding an International Advisory Board conference with a panel of eleven Key Opinion Leaders in rheumatoid arthritis from Austria, Switzerland, and Spain focused on Piclidenoson.

Gebro Pharma has licensed the distribution rights to Piclidenoson for the indications of rheumatoid arthritis and psoriasis in Austria, Switzerland, and Spain. The purpose of the meeting, which is taking place in Fieberbrunn, Austria, Gebro Headquarters, on October 17-18, 2019, is to conduct a scientific review of Piclidenoson, the role of the Adenosidne receptor A3 and mechanism of action of the molecule and aspects related to patient populations. Can-Fites CEO Dr. Pnina Fishman, Medical Director Dr. Michael Silverman, and VP Business Development Dr. Sari Fishman are delivering presentations at the conference together with the participation of European Key Opinion Leaders in rheumatoid arthritis, Dr. Burkhard Leeb and Dr. Sander W. Tas.

Can-Fite is currently enrolling 500 patients in Europe, Canada, and Israel in a Phase III study of Piclidenoson as a first-line treatment for rheumatoid arthritis. The study will evaluate Piclidenoson as compared to placebo, and compared to methotrexate, the current standard of care for first-line treatment of rheumatoid arthritis.

This highly productive forum with our distribution partner Gebro is an opportunity for us to engage directly with their network of doctors in Europe regarding how Piclidenoson may meet an unmet need for patients who seek a safe and effective treatment for newly diagnosed rheumatoid arthritis, stated Can-Fite CEO Dr. Pnina Fishman.

Gebro considers Piclidenoson as an important milestone to strengthen its competence in the treatment of RA and psoriasis and to provide patients with an innovative concept of treatment for such diseases, stated Gebro Pharma CEO Dr. Christian Kollenz.

About Piclidenoson

Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. Piclidenoson is currently under development for the treatment of autoimmune inflammatory diseases. It is being evaluated in a Phase III study as a first line treatment for rheumatoid arthritis and a Phase III study in the treatment of moderate-to-severe psoriasis.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

About Gebro Pharma

Gebro Pharma is a privately-owned leading pharma group founded in Austria in the late 1940s, with over 500 employees and more than 70 years of experience in research, manufacturing and marketing of pharmaceutical specialties. Its headquarters are located in Fieberbrunn (Austria), where Gebro is one of the main local players, with commercial operations also in Spain and Switzerland. With a total turnover of 185M in 2018, Gebro is positioned as a leader in pain and rheumatology with a strong portfolio.

Story continues

Additionally, Gebro Pharma has also built a portfolio around urology, respiratory, dermatology, GI and CV depending on the territory.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should or anticipate or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please visit:

http://www.gebro.es

DISCLAIMER

In compliance with article 101.c) 16 of Law 29/2006, this press release can only be circulated to specialized media addressed to authorized personnel for the prescription or dispensation of drugs.

LABORATORIOS GEBRO PHARMA S.A. will hold responsible anyone who acts contrary to our indications in terms of dissemination of information for all the consequences and/or claims from third parties that may arise from the breach.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005438/en/

Visit link:
Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment...

October 12 is World Arthritis Day.

An incredibly common condition, it currently affects one in five people living in Ireland today. Despite this, our understanding of arthritis - and osteoarthritis - can sometimes be lacking.

Senior lecturer in physiotherapy at RCSI and musculoskeletal clinical specialistDr Helen French says that the most common myth about osteoarthritis is that it only affects older people.

And the second most common myth is that all older people are bound to get it.

We think about osteoarthritis as only affecting older people, but wed like to get the message across that thats not just the case," she says.

"People have a fear of osteoarthritis, or they think its normal if youre old and that its just part of regular ageing - but its not.

"Joint replacement is for the minority, not everybody will have to have a joint replaced."

In Ireland, one in five people will be diagnosed with some form of arthritis in their lifetime.

Women are two to three times more likely to be diagnosed withosteoarthritis too, with 18 percent ofarthritis patients in Ireland being less than 55 years old.

The most common form of arthritis, osteoarthritis, causes damage to joints by wearing down the protective cartilage that cushions the ends of the bones.

It tends to relate to joints in the knees, hips, and spine more severely, but any joint in the body can be affected by the condition.

Theres a few different risk factors," says Dr French. "Sometimes its genetics, other times its obesity because weight is a critical factor."

"It could also be caused by a hormonal influence though there isnt substantive evidence to prove that."

Dr French says that despite misconceptions about the condition, more and more people under the age of 45 are being diagnosed with osteoarthritis.

A lot of them are young women and - in particular - young sporting women.

"Not a lot of women think about this," she says. "Sportswomen would be high risk because if youre a high level athlete and youre doing a twisting-turning sport like soccer or rugby, then you can easily injure the ligaments in your knee or your ankle.

"Men can often get similar injuries playing the likes of GAA, but it is more common in women because of our biomechanics and because of the way we move.

"Research has shown that young sportswomen are more at risk of developing osteoarthritis 10 years after they start playing (...)but the key message were trying to get across is that preventative measures are possible."

Osteoarthritis affects a person's day-to-day life. Everything from getting up in the morning to getting out of a chair to driving a car can be affected by the condition.

The stiffness caused by joint movement can also have a knock on effect on how a person partakes in hobbies or sport - and even on how they do their job.

"It does affect every day activities that we take for granted," says Dr French. "You can have a really high quality of life with osteoarthritis, but to ensure this we need to have a better understanding of the condition, as well as how to manage it."

There are three core recommendations for dealing with osteoarthritis as a young person.

The first is weight management as obesity has been proven to increase a person's risk of developing the condition.

The second is exercise and the third is self-management, with medication to ease the symptoms of the condition being on the second line of control.

Dr French says that another one of the most common myths abut osteoarthritis is that you shouldn't exercise when you have it when, in fact, you should.

"You should exercise more than normal," she says. "You may need to go to a physiotherapist and get an individual approach to suit your needs and make sure youre doing the right type of exercise, like a specific strengthening exercise.

"The needs should suit the person, but you should definitely be doing it.

You can find out more about osteoarthritis via Arthritis Ireland here.

If you are concerned about your health, you should always contact your GP.

Read more:
Osteoarthritis and arthritis: it's not only older people who are at risk - Her.ie

Arthritis is very prevalence among the old age persons. This is more prevalent than diabetes like AIDS and cancer etc. Lets read about the Arthritis on the occasion of World Arthritis Day.

What is Arthritis?

Arthritis literally means the swelling and tenderness of one or more joints which leads to pain and stiffness in the joints. There are various types of arthritis. Rheumatoid arthritis is an autoimmune condition that can affect people at any age while osteoarthritis is the most common reason for age-related joint pain.

The main symptoms of arthritis are pain and stiffness in joints which usually worsen with age. But don't think that arthritis is inevitable in the old age persons.

History of World Arthritis Day:

October 12 is celebrated as World Arthritis Day since 1996. It was started by the Arthritis and Rheumatism International (ARI) to increase global awareness about the rheumatic and musculoskeletal diseases (RMD).

What is Ebola Virus?

World Arthritis Day 2019 Theme:

Each World Arthritis Day has a theme since 2017. The theme of year 2017 was Dont Delay, Connect Today which continue till 2018. The theme for World Arthritis Day 2019 is "Time2Work". This theme would be followed in the financial year 2020 also.

Worth to mention that before 2017, World Arthritis Day; didnt have any theme.

The European League Against Rheumatism, (EULAR's) campaign

The "Dont Delay, Connect Today" campaign targets to highlight that early diagnosis of rheumatic and musculoskeletal diseases (RMD) and access to treatment can prevent further damage.

Patients of the World Arthritis Day

Arthritis affects around 15% people i.e. over 180 million people in India. World Health Organization (WHO) data show that 0.3-1% of the worlds population has rheumatoid arthritis and, 18% women while around 10% men above the 60 years have symptomatic osteoarthritis.

There are around 120 million people are currently living with a rheumatic disease (RMD) in the European Union alone.

The World Arthritis Day is dedicated to raise awareness about Arthritis; affecting people with rheumatic and musculoskeletal diseases. An organisation European League Against Rheumatism (EULAR) tries its best efforts to promote the awareness about the World Arthritis Day and its importance. EULAR also sets the theme for this day.

Treatment of the Arthritis

Osteoarthritis is a age related problem which can also be mitigate by drinking more than 2 litres of water a day, avoidance of fatty & oily food and sweetened beverages while inclusion of good vegetarian protein diet and Physiotherapy treatment.

So this was the complete detailed information on the World Arthritis Day 2019. The theme of World Arthritis Day 2019 "Time2Work"is very important for various exams hence be attentive about it.

World Hepatitis Day 2019: Current Theme, History and Significance

Here is the original post:
World Arthritis Day 2019: History and Theme - Jagran Josh

AUSTIN (Nexstar) For about three decades,parts of Isha Dhars skin have lostcolor.

Ive had vitiligo since I was five, she said.It happens, stops, happens, stops.

Vitiligo is a medical condition where patches in the skin lose pigment.A person who has vitiligo can either have one patch or multiple patches of lighter skin on theirface, arms, legs or other parts of their body.It can also affect hair.

Its not completely understood what causes vitiligo, but its thought that the immune system does play a role in potentially getting some of these skin cells that cause pigment or what gives your skincolor to stop working,said Dr.Lia Gracey, MD, PhD, a dermatologist with Baylor Scott & White Health.Vitiligo doesnt currently have a cure and it can be difficult to treat because vitiligo can be progressive with more and morecolorloss.

There are currently several treatment options to help with vitiligo,includingcreams, phototherapy, surgery and oral medication.But there is no cure.

Its not like it stops you from doing your regular work, Dhar said. Its not a debilitating condition in any way. It doesnt stop you from living your regular life.

But Dhar and dermatology experts say a lack of awareness can cause people to lose self-esteem and be self-conscious about their bodies. Thats whereitcan get tough.

Youre sort of, in some ways, different from every other person, Dhar said. It stands out and people stare. It is a very large lack of awareness and I feel like if more people knew about it, it might help to lessen the stares or questions.

In 2018,Winnie Harlow,a Canadian fashion model,was the first model with vitiligo to walk in the Victorias Secret Fashion Show.

Any step toward a truly equal and diversemodelingindustry is great, but for a huge brand like Victorias Secret to include models with skin conditions like vitiligo is a huge step to normalizing it in the entire industry, she said in a Teen Vogue interview. I hope that theres many more in the future. We need to work toward diversity, not for the sake of it, but to make it the norm. And I hope that this is a big step toward that.

TeVidoBioDevices,an Austin-based biotechnologystartup, is working on a treatment calledTruPigmentto help patients with vitiligo.During a patients first visit, the doctor will take a small sample of the persons healthy skin through a process called cellular grafting and will send this sample toTeVidoBioDevices. The company then takes the living skincells and places it in a liquid, which is theTruPigment, and then sendsit backto the doctors office.CEO Laura Bosworth says doctors can use it treat an area almost five times the skin samples size and its expected thatcolorwill come back in about two months.

[The doctor] just takes off that little thin sheet of skin in the area that youre planning to treat and then theres a little syringe of your cells in a liquid, she explained. You squirt it on, spread it around and bandage it up.

Dr.Ammar Ahmed, associate professor in the Division of Dermatology at Dell Medical School at the University of Texas at Austin, is working with the four patients who are seekingTruPigmentas a treatment for their vitiligo. Dhar is one of his patients. Ahmed is hopeful results can lead to somecolorcoming back in her and others skin.Dr.Ahmed says there are some layers of challenges patients face in accessing any treatments for vitiligo, because insurance companies view it as a cosmetic condition, rather than medical.

Right now, these types of grafting procedures are generally not covered by insurance companies in the United States, he explained. For the first several patients weve done, weve done it at a discount because theyre the first patients to be using this. It is a significant investment to get it done.

Dhar says shes tried othertreatments, butdidnt see much improvement. She is hopeful this treatment will add another option for treatment and raise public awareness about the skin condition.

I felt like giving it a little bit of a nudge with theTeVidotreatment would be a helpful thing, she said. I dont know the results yet.

Lets see, she added. Im keeping my fingers crossed.

View original post here:
Austin biotechnology company hopes to help patients with vitiligo - WWLP.com

A new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment.

The organoid-based test, developed by the group of Emile Voest at Netherlands Cancer Institute in Amsterdam, in a prospective clinical trial correctly predicted responses in 80% of metastatic colorectal cancer (mCRC) patients treated with irinotecan chemotherapy without misclassifying patients who benefited from the chemotherapy. Patient-derived organoids, however, failed to predict outcome for treatment with 5-fluorouracil plus oxaliplatin. Thus, its medical utility is limited to stratification of patients for irinotecan chemotherapy, in a stage of tumour development that cannot be cured.

Specifically, the researchers collected samples from 61 patients with mCRC and used the tissue to generate three-dimensional tissue cultures, which they treated with irinotecan either alone or in combination with the chemotherapy 5-Fluorouracil. The organoids, which could be generated and screened within 21 days generally reflected how the patients responded to the treatments.

Read more from the original source:
Patient's organoids predict response to chemotherapy - European Biotechnology

DUBLIN--(BUSINESS WIRE)--The "Global Longevity and Anti-Senescence Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on the study of genomics, microbiome, bioinformatics, and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy, and Others. Senolytic drug therapy held the largest market revenue share in 2017. The fastest growth of the gene therapy segment is due to the Large investments in genomics.

Report Scope

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.

The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Global Longevity and Anti-senescence Market by Therapy

Chapter 5 Global Longevity and Anti-senescence Market by Application

Chapter 6 Global Longevity and Anti-senescence Market by Region

Chapter 7 Industry Structure in Longevity and Anti-senescence Market

Chapter 8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/zy7jt

See original here:
Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 - ResearchAndMarkets.com - Business Wire

We will be comparing the differences between Cellect Biotechnology Ltd. (NASDAQ:APOP) and Vaxart Inc. (NASDAQ:VXRT) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Demonstrates Cellect Biotechnology Ltd. and Vaxart Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents Cellect Biotechnology Ltd. (NASDAQ:APOP) and Vaxart Inc. (NASDAQ:VXRT)s return on assets, return on equity and net margins.

Insider and Institutional Ownership

Roughly 0% of Cellect Biotechnology Ltd. shares are held by institutional investors while 34.2% of Vaxart Inc. are owned by institutional investors. About 54.73% of Cellect Biotechnology Ltd.s share are held by insiders. Competitively, Vaxart Inc. has 3.2% of its share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Cellect Biotechnology Ltd.s stock price has bigger decline than Vaxart Inc.

Summary

Cellect Biotechnology Ltd. beats Vaxart Inc. on 6 of the 9 factors.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Contrasting of Cellect Biotechnology Ltd. (APOP) and Vaxart Inc. (NASDAQ:VXRT) - MS Wkly

We are comparing Unity Biotechnology Inc. (NASDAQ:UBX) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Table 1 demonstrates Unity Biotechnology Inc. and Aeglea BioTherapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Liquidity

Unity Biotechnology Inc.s Current Ratio is 13.7 while its Quick Ratio is 13.7. On the competitive side is, Aeglea BioTherapeutics Inc. which has a 10.7 Current Ratio and a 10.7 Quick Ratio. Unity Biotechnology Inc. is better positioned to pay off short and long-term obligations compared to Aeglea BioTherapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 72.8% of Unity Biotechnology Inc. shares and 78.8% of Aeglea BioTherapeutics Inc. shares. 8.3% are Unity Biotechnology Inc.s share owned by insiders. Comparatively, 1.2% are Aeglea BioTherapeutics Inc.s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Unity Biotechnology Inc. had bearish trend while Aeglea BioTherapeutics Inc. had bullish trend.

Summary

On 7 of the 9 factors Unity Biotechnology Inc. beats Aeglea BioTherapeutics Inc.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companys lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Unity Biotechnology Inc. (UBX) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) Contrasting side by side - MS Wkly

The Biotechnology Instrumentation Market study formulated by DataIntelo, presents a detailed analysis of the influential trends prevailing in this business sphere. This research report also offers definitive information concerning the commercialization of this vertical, market size, and revenue estimation of this industry. The study explicitly illustrates the competitive standing of key players over the projected timeline while incorporating their individual portfolios & geographical expansion.The Global Biotechnology Instrumentation market 2019 research provides a detailed information of the industry including classifications, applications and industry chain structure. The Global Biotechnology Instrumentation Industry analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Request for Sample of this [emailprotected] https://dataintelo.com/request-sample/?reportId=83280

Top Key Players included in this report:Agilent Technologies (USA) Beckman Coulter (USA) Bio-Rad Laboratories (USA) Bruker (USA) GE HealthCare (UK) Gilson (USA) Harvard Bioscience (USA) Hitachi High-Technologies (Japan) Illumina (USA) Lonza (Switzerland) PerkinElmer (USA) Roche Diagnostics (Switzerland) Shimadzu (Japan) Siemens (USA) Thermo Fisher Scientific (USA) Waters (USA)

Market segment by Type, the product can be split intoElectrophoresis Immunoassay Chromatography Imaging Mass Spectroscopy Microarray Technology Laboratory Automation

Market segment by Application, split intoPharmaceutical Companies Research Institutes Biotech Companies

Enquiry Before Buying: https://DataIntelo.com/enquiry-before-buying/?reportId=83280

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Report Content Overview: Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors Provision of market value (USD Billion) data for each segment and sub-segment Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions Includes an in-depth analysis of the market of various perspectives through Porters five forces analysis Provides insight into the market through Value Chain Market dynamics scenario, along with growth opportunities of the market in the years to come

Request for Discount of this Report: https://dataintelo.com/ask-for-discount/?reportId=83280

We also offer customization on reports based on specific client requirement:1- Free country level analysis for any 5 countries of your choice.2- Free Competitive analysis of any market players.3- Free 40 analyst hours to cover any other data points

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataInteloName Alex MathewsEmail [emailprotected]Organization DataInteloAddress 500 East E Street, Ontario, CA 91764, United States.

Follow this link:
Biotechnology Instrumentation Market Research Report Analysis And Forecasts To 2025 - Statsflash

Opthalmology Drugs and Devices Market Report is a complete assessment of current status, trends and respective shares of some of the most prominent players in this landscape. The study contains thoughtful insights, facts, Opthalmology Drugs and Devices historical data, and statistically supported and industry-validated market data. This Opthalmology Drugs and Devices report also explores Business models, Key strategies and Growth opportunities in upcoming years.

The Opthalmology Drugs and Devices market report examines the economic status and prognosis of worldwide and major regions, in the prospect of all players, types and end-user application/industries; this report examines the most notable players in major and global regions, also divides the Opthalmology Drugs and Devices market by segments and applications/end businesses.

Request for Free Sample Copy at: http://www.researchreportcenter.com/request-sample/1254902

Merck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch & Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson & Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

Global Opthalmology Drugs and Devices Market insights cover traits, growth, and size, segmentation, regional retreats, competitive landscape, shares, trends, and plans. The attributes part of this Opthalmology Drugs and Devices report defines and explains the growth. The market size department gives industry earnings, covering the historical growth of this and predicting the long run. Opthalmology Drugs and Devices Drivers and restraints with the variables affecting the growth of this market. The segmentations divide the essential Opthalmology Drugs and Devices sub-industries that form the market.

North America, China, Rest of Asia-Pacific, UK, Europe, Central & South America, Middle East & Africa

Get Discount on this Report: http://www.researchreportcenter.com/check-discount/1254902

The Opthalmology Drugs and Devices analysis incorporates historical data from 2014 to 2019 and predictions until 2025 helping to make the reports a valuable resource for industry executives, promotion, product and sales managers, advisers, analysts, and different people trying to find vital Opthalmology Drugs and Devices industry data in readily accessible records with clearly exhibited tables and charts.

Customization of the Report: This report can be customized as per your needs for additional data or countries.Please connect with our sales team (sales@researchreportcenter.com)

The rest is here:
Opthalmology Drugs and Devices Market Professional Survey and In-Depth Analysis Research Report Foresight to 2025 - Finance Daily Tribune

Active Pharmaceutical Ingredients (API) market size was valued at USD 158.5 billion in 2016 and is projected to reach to USD 297.4 billion by 2026 at a CAGR of 6.5%.This is a comprehensive global report focused on the current and future prospects of the active pharmaceutical ingredients market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and microenvironmental factors. An in-depth analysis of past trends, future trends, demographics, and technological advancements for the active pharmaceutical ingredients market has been done in order to calculate the growth rates for each segment and sub-segments.

An active pharmaceutical ingredient is a biologically active portion of a pharmaceutical drug intended to perform certain pharmacological actions or have prominent effects for the diagnosis, cure, treatment or prevention of chronic and acute diseases.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/1816

The rising prevalence of chronic diseases and increasing uptake of biopharmaceuticals is expected to majorly drive the market growth.

As per data published by the World Health Organization (WHO), chronic disease prevalence is anticipated to rise by 57.0% by the year 2020. The number of people suffering from diabetes in developing countries was 84.0 million in 1995, which is projected to increase by 2.5-fold to 228.0 million in 2025. Chronic diseases include diabetes, obesity, and cardiovascular diseases, cancer, neurological diseases, and other diseases; the rise in prevalence of these diseases are augmenting the demand for treatment that may support the market growth over the forecast period.

Furthermore, augmented demand for rapid-acting & efficient drugs and the emergence of innovative drug manufacturing facilities are expected to assist in market growth during the forecast period.

Loss of drug exclusivity is impeding the revenue growth!

Patent expiration is accountable for the huge loss for pharmaceutical firms in terms of revenue, which is anticipated to impede the market growth during the forecast period.

The biotech APIs segment is expected to witness significant market growth.

The biotech APIs segment is expected to register comparatively higher CAGR over thee forecast period owing to high R&D for novel biosimilar drugs, escalating demand for protein-based therapeutics, and rising key traditional manufacturers focus toward biological drugs.

The branded/innovative drugs segment spearheaded the market.

A surge in prescription rates and drug prices coupled with higher spending on R&D activities are expected to contribute to the dominance of the branded/innovative drugs segment.

The merchant manufacturers segment is expected to witness lucrative market growth.

Worldwide rising outsourcing of API/drug molecule formulation from drug manufacturers in order to eliminate the need for heavy investment in manufacturing processes.

North America is expected to hold a major chunk of the market during the forecast period.

North America is anticipated to hold substantial market share over next ten years owing to the presence of favorable government initiatives, changing lifestyle leads to the development of diseases, rising investment on R&D, and technological developments in drug manufacturing processes.

Key Highlights:

Active pharmaceutical ingredients market size analysis and forecast Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the active pharmaceutical ingredients market Active pharmaceutical ingredients market segmentation on the basis of synthesis type, drug type, manufacturer type, therapeutic area, and geography (regional) Active pharmaceutical ingredients market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of a study Active pharmaceutical ingredients market analysis and forecast for five major regions such as North America, Europe, Asia Pacific, Latin America, and MEA. Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies Competitive landscape of the key players operating in the active pharmaceutical ingredients market including competitive developments, investments, and strategic expansion

Years that have been considered for the study are as follows:

Base Year 2016 Estimated Year 2017 Forecast Period 2017 to 2026

For company profiles, 2016 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for active pharmaceutical ingredients market.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/1816

Some of the key players of the active pharmaceutical ingredients market include:

AbbVie Inc. Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Cipla Inc. Merck & Co., Inc. Eli Lilly and Company Mylan N.V. Teva Active Pharmaceuticals Industries Ltd. Aurobindo Pharma Sun Pharmaceutical Industries, Ltd. Dr. Reddys Laboratories Ltd. Albemarle Corporation

Key Target Audience:

Healthcare companies Corporate healthcare entities Government agencies Market research and consulting firms Venture capitalists Technical StudentsScope of the Active Pharmaceutical Ingredients Market Report:

The research report segments the active pharmaceutical ingredients market based on synthesis type, drug type, manufacturer type, therapeutic area, and geography.Active Pharmaceutical Ingredients Market, By Synthesis Type

Biotech Monoclonal Antibodies Recombinant Proteins Vaccines SyntheticActive Pharmaceutical Ingredients Market, By Drug Type

Branded Drugs Generic Drugs Over-the-counter (OTC) DrugsActive Pharmaceutical Ingredients Market, By Manufacturer Type

Captive Manufacturers Merchant ManufacturersActive Pharmaceutical Ingredients Market, By Therapeutic Area

Cardiology Pulmonology Opthalmology Neurology Oncology Orthopedics OthersActive Pharmaceutical Ingredients Market, By Geography

North America U.S. Canada Europe UK Germany France Italy Spain Rest of Europe Asia Pacific Japan China India Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America MEA South Africa Saudi Arabia Rest of MEA

Geographic Analysis:

Breakdown of North America Active Pharmaceutical Ingredients Market Breakdown of Europe Active Pharmaceutical Ingredients Market Breakdown of Asia Pacific Active Pharmaceutical Ingredients Market Breakdown of Latin America Active Pharmaceutical Ingredients Market Breakdown of MEA Active Pharmaceutical Ingredients Market

MAJOR TOC OF THE REPORT

Chapter One: Active Pharmaceutical Ingredients (API) Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Active Pharmaceutical Ingredients (API) Market Competition, by Players

Chapter Four: Global Active Pharmaceutical Ingredients (API) Market Size by Regions

Chapter Five: North America Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Six: Europe Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Seven: Asia-Pacific Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Eight: South America Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Active Pharmaceutical Ingredients (API) by Countries

Chapter Ten: Global Active Pharmaceutical Ingredients (API) Market Segment by Type

Chapter Eleven: Global Active Pharmaceutical Ingredients (API) Market Segment by Application

Chapter Twelve: Global Active Pharmaceutical Ingredients (API) Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Active Pharmaceutical Ingredients (API) Market Report at: https://www.maximizemarketresearch.com/market-report/active-pharmaceutical-ingredients-api-market/1816/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

The rest is here:
Active Pharmaceutical Ingredients (API) Market Global Industry Analysis and Forecast (2017-2026 - Markets Gazette

The company expands its Scientific Advisory Board with four additional RNA splicing, genetics, and disease experts, who join SAB Chair Professor Tyler Jacks & special advisor Professor Phil Sharp as well as several other internationally-recognized SAB members.

WALTHAM, Mass., Oct. 15, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. ("Skyhawk"), a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression, today announced the appointment of four additional internationally recognized experts in RNA biology and disease to its Scientific Advisory Board.

Skyhawk Therapeutics, Inc. (PRNewsfoto/Skyhawk Therapeutics)

"I am thrilled that we have assembled such a stellar group of RNA biology and human disease experts for Skyhawk's Scientific Advisory Board," said Prof. Tyler Jacks, Director of MIT's Koch Institute for Integrative Cancer Research and Chair of Skyhawk's SAB. "We look forward to having their combined knowledge and wisdom help guide Skyhawk's research and development efforts, to progress even more rapidly towards groundbreaking new approaches and therapies for patients with a variety of difficult-to-treat diseases."

Prof. Ben Blencowe is an internationally recognizedRNA biologist who has made pioneering contributions to the understanding of the molecular mechanisms controlling alternative splicing and their roles in evolution, development and disease. He holds the Banbury Chair of Medical Research and is Professor in the Donnelly Centre at the University of Toronto; he also serves as Director of the Donnelly Sequencing Centre. Prof. Blencowe has received numerous awards and honors for his research excellence and was recently elected Fellow of the Royal Society (UK).

Dr. Ben Ebert is the George P. Canellos, MD and Jean S. Canellos Professor of Medicine at Harvard Medical School, and Chair of Medical Oncology at the Dana-Farber Cancer Institute. His research focuses on the genetics, biology, and therapy of myeloid malignancies. His work has led to the characterization of clonal hematopoiesis as a pre-malignant state for hematologic malignancies, and elucidation of the mechanism of action of lenalidomide and related molecules that induce degradation of specific proteins. Dr. Ebert has served as president of the American Society for Clinical Investigation and is an elected member of the National Academy of Medicine and the Association of American Physicians.

Prof. Jeannie T. Lee is Professor of Genetics and Pathology at Harvard Medical School, the Blavatnik Institute, and the Massachusetts General Hospital. She specializes in the study of epigenetic regulation by long noncoding RNAs and uses X-chromosome inactivation as a model system. Prof. Lee also translates basic knowledge to find treatments for genetic disorders and co-founded two publicly traded companies Translate Bio and Fulcrum Therapeutics. She is a Member of the National Academy of Sciences, a 2018 Harrington Rare Disease Scholar, the 2016 recipient of the Lurie Prize, a 2016 recipient of the Centennial Award from the Genetics Society of America, the 2010 awardee of the Molecular Biology Prize from the National Academy of Sciences, and a Fellow of the American Association for the Advancement of Science.

Prof. Maurice Swanson is an expert on the regulation of RNA alternative processing during mammalian development and how this regulation is disrupted in neurological and neuromuscular diseases, including some types of muscular dystrophy and amyotrophic lateral sclerosis (ALS). Prof. Swanson is a Professor in the Department of Molecular Genetics and Microbiology at the University of Florida College of Medicine and Associate Director of the Center for NeuroGenetics. His lab focuses on the functions of repetitive DNA elements, particularly microsatellites or short tandem repeats (STRs), in RNA-mediated disorders. An important objective of these studies is to enhance tissue regeneration following treatment modalities designed to block the toxicity of STR.

Story continues

These four new members join Skyhawk's existing Scientific Advisory Board members & advisors including:

About Skyhawk TherapeuticsSkyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTAR (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.

For more information visit: http://www.skyhawktx.com, https://twitter.com/Skyhawk_Tx, https://www.linkedin.com/company/skyhawk-therapeutics/

SKYHAWK MEDIA CONTACT:Anne Deconinckanne@skyhawktx.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/world-renowned-experts-appointed-to-skyhawk-therapeutics-scientific-advisory-board-300938290.html

See the original post here:
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board - Yahoo Finance

Article body copy

Researchers have found three new-to-science viruses in chinook and sockeye salmon in British Columbia. The discovery, led by Gideon Mordecai, a University of British Columbia molecular biologist who studies the ecology of viruses, is part of a larger investigation into whether viruses are contributing to the steep declines in wild British Columbia salmon populations over the past 30 years. The researchers now aim to find out if these infectious agents are being transmitted from farmed to wild fish. Whether farmed fish sicken wild fish is a key concern of fishers; local First Nations, for whom salmon is a critical part of their livelihoods and cultures; and people who worry about the fate of the struggling, chinook-eating southern resident killer whales.

Of the three new viruses, one, an arenavirus, was found in farmed, hatchery, and wild chinook and sockeye salmon. A nidovirus was found in farmed, hatchery, and wild chinook. And a reovirus was found only in farmed salmon.

Arenaviruses are known to primarily infect mammals, so the researchers were surprised to find one in salmon. Farmed fish with the arenavirus had anemia and damage to their gills, kidneys, spleens, swim bladders, and livers. The nidovirus is from a group that includes the viruses behind severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which affect mammals lungs. This nidovirus was mostly found in the salmons gills. The reovirus is related to viruses that cause hemorrhagic diseases that have killed many fish in Chinese aquaculture.

The discoveries contribute to a growing understanding of the threats facing British Columbias wild salmon.

A decade ago, people thought the main causes of salmon population declines were development of land around rivers, which makes streams warmer and pushes sediment into rivers, and climate change, which warms the ocean and causes currents and prey species to move. But in 2011, Kristi Miller, head of molecular genetics at the Pacific Biological Station in Nanaimo, British Columbia, showed that infectious diseases may be contributing as well.

In 2013, Miller became the head of genomic research for the Strategic Salmon Health Initiative, a collaboration among Fisheries and Oceans Canada, and the nonprofits Pacific Salmon Foundation and Genome BC.* This new study is one of more than 30 the initiative has done to investigate the population declines.

In the project, Mordecai, Miller, and their colleagues first studied dead and dying farmed chinook and used DNA analyses to identify the previously unknown viruses.

They looked at the farmed fish first because it is difficult to find diseased fish in the wild. On fish farms, diseases are much more obvious because fish are routinely found dead or dying with abnormalities on their bodies. As with any type of factory farming, the unnatural, crowded conditions of fish farms foster disease. Sick wild fish dont usually die from their diseases, says Miller. As soon as their swim performance or visual acuity is affected, theyre eaten. This is a big part of why salmon viruses are understudied, says Mordecai.

But thanks to new tools, Mordecais team was able to find the viruses in wild salmon, which they had collected and tested in the lab. Although the wild fish were not yet showing evidence of disease, the researchers used molecular analyses to see if their immune responses were triggered by a virus. If researchers could not detect a known virus, they looked for new viruses using next-generation DNA sequencing that allowed them to map genomes quickly, searching much more broadly than earlier methods. This is so incredibly powerful; it essentially allows fish to talk to us, says scientist turned activist Alexandra Morton, who was not involved with this study.

Although the scientists found that the viruses were infecting the salmons cells, they have not proved that they cause diseases, says Mordecai. Although it might seem obvious to assume that dead farmed salmon died from disease, their deaths could be caused by something other than the viruses in question. Linking the new viruses to diseases is the next research step.

The scientists are also unsure if the viruses are being passed between farmed and wild fish. They tested chinook and sockeye salmon from different locations as a first step to understanding possible transmission. Then they will use genomic sequencing to see whether viruses found in different populations are the same. Tracking transmission is relatively easy to do with viruses because they mutate rapidly so you can follow the transmission pathway, says Miller.

As Mordecai puts it: If you infected me with a cold virus, we could look at the sequence of the virus in me and the virus in you and see theyre closely related. Whereas a virus someone picked up a six-hour drive away or in the UK might be different.

First Nations activists who are fighting fish farms in their territories feel certain that farmed fish are spreading disease to wild fish. Chief Ernest Alfred of the Namgis First Nation in Alert Bay occupied the Swanson Bay fish farm in protest for 280 days. He and other occupiers took daily photos of sick fish, including some that were deformed or yellowing, a sign of jaundice. There were also all sorts of skin disorders, there was blindness. Hes also seen wild salmon in British Columbias rivers and streams with similar symptoms, many of which die before spawning.

Despite recent studies highlighting the likelihood of transmission of another virusPiscine orthoreovirusfrom farmed to wild salmon, neither government nor industry has taken preventative action, such as testing farmed fish prior to moving them to ocean pens. In the current federal election campaign, the Liberal and Green parties announced a commitment to phase out ocean fish farms by 2025. But Alfred and Morton, who are following political developments closely, say they remain skeptical that government will get tough on industry to protect wild salmon.

Miller also questions whether election promises will translate into real change, but she is encouraged that public pressure is having an effect. As for whether that results in shifts in policies and regulations, we have to wait and see, she says.

Correction: Genome BC is a nonprofit, not a private company.

Read more from the original source:
New Viruses Found in Farmed and Wild Salmon - Hakai Magazine

Why anyone feels the need to keep remaking shows again and again is hard to imagine, but apparently enough people are willing to sit through another version of a show that they might have watched when it first aired simply because theres a new cast and, as a lot of people are praising, its more diverse now. Neetha K of Meaww still isnt convinced and I cant blame her. Im still trying to figure out how thats going to immediately make the show better but its definitely appeasing the people who have presented the loudest and most insistent voices throughout the years but havent seemed to realize that if actors are going to be selected they have to actually know how to act and not get their parts based on their race, gender, or any other factor apart from their talent. As if this wasnt enough, the middle sister is a lesbian and they all play Latina sisters despite the fact that one of them is Afro-Caribbean, one is Puerto Rican, and the other is a mix of African American, English, and Indigenous Canadian. At this point just using names must be too difficult since so many people have to display their pedigree so that others know how to address and think about them. At any rate, here are the cast members that are currently rounding out the second season of Charmed.

The middle sister of the bunch is portrayed as a very strong-willed feminist and is also an activist. Shes a graduate student and as mentioned is an open lesbian that had to wipe the memory of herself from her lovers mind. The power shes been given is to freeze time, which seems like a rather dangerous power when one really stops to think about it since the implications for such a thing are kind of dire. Eventually though it was revealed that Mel is the half-sister and not Macy.

Macy is a lot more practical than her sisters and is even labeled as a science nerd in a way. She has her PhD in molecular genetics and eventually moves to Hilltowne to work in the university. The revelation that she has two half-sisters in town is something of a shock but is necessary since the story kind of hinges on the trio getting together and discovering their powers so that they can act as the saviors of the town. The power she wields is telekinesis, being able to move objects with her mind, and once again its kind of a dangerous power to have but one that seems a lot more common in supernatural tales.

Maggie is the youngest and most upbeat of the sisters and shes the only one of them that seems to want to hide what she is and not really embrace it as shes trying to pledge a sorority and being a witch could ruin everything. Instead of having the power of premonition however as was seen in the original show Maggie has the power of empathy, meaning that she can read the emotions of other people and understand what theyre feeling and their emotional state at that moment. This is perhaps the most passive of the powers that the witches possess and seems as though it might be kind of useless, but it has shown to be an asset in past movies and shows that have utilized it.

Harry is the guy thats known as a Whitelighter, a guardian angel that protects and guides the witches when hes needed. Its kind of amusing in such a woke show that theres still a white male that is being used as a guide and a mentor for three diverse young women that are bound to become stronger when they unite, but it does seem to be introduced as a positive idea since hes more hands off and allows them to simply learn the ropes on their own while sticking around to see how things go.

You had to know that there would be a demon presence in this show and that eventually it would end up coming down to being one of the love interests of one of the witches. Maggie and Nick obviously cant stay together since he has to deal with the demon side of his being, but it feels safe to say that hell be back at some point since the two of them share something thats not bound to be thrown away.

It would seem that as different as the show is striving to be that there are still a lot of similarities that are being kept for good or ill, and at this moment its hard to say whether or not its bound to continue for more than a couple of seasons. As of now season 2 has been approved as per Abby Robinson of DigitalSpy, but its going to have step things up if it wants to improve.

Follow this link:
Meet The Cast of Charmed Season 2 - TVOvermind

NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the Company will give an oral presentation of data at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston (October 15-19) on AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia. In addition, the Company will host an ASHG Educational Symposium featuring a panel of Galactosemia experts.

Details on the Oral Presentation and Educational Symposium are below:

Oral Presentation

Title: AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue Specific Abnormalities of Galactosemia, in a GALT Deficient Rat Model of DiseaseDate and Time: Saturday, October 19, 2019, 8:30-8:45am CTPresenter: Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied TherapeuticsSession: 99Location: Room 370A Level 3/Convention Center

The presentation will be available on the ASHG conference website as well as the Applied Therapeutics website following the session.

Galactosemia Educational Symposium

Title: Development of an Oral Treatment for GalactosemiaDate and Time: Thursday, October 17, 2019, 12:45-2:00pm CTLocation: Marriott Marquis Houston, Room Briargrove AB, Level 3Key Topics:

Additional details for the event can be found here.

About Galactosemia Galactosemia is a rare metabolic disease that affects how the body processes a simple sugar called galactose, and for which there is no known cure or approved treatment available. Galactose is found in foods, but the human body also naturally produces galactose on its own, so dietary restriction cant prevent complications of disease. It is estimated that the U.S. Galactosemia population is approximately 2,800 patients, based on newborn screening data identifying 2,500 infants through 2014, and the estimated birth rate of 80 patients per year. High levels of galactose circulating in the blood and tissues of Galactosemia patients enables Aldose Reductase to convert galactose to a toxic metabolite, called galactitol, which causes long-term complications ranging from CNS dysfunction to cataracts.

About AT-007AT-007 is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia. AT-007 has been studied in in an animal model of Galactosemia, which demonstrated that AT-007 reduces toxic galactitol levels and prevents disease complications.Applied Therapeuticsis conducting a biomarker based development program in patients with Galactosemia, based on the recently released draft industry guidance on drug development for low prevalence, slowly progressing rare metabolic diseases. The company received Orphan Designation for AT-007 for Galactosemia inMay 2019.

About Applied TherapeuticsApplied Therapeuticsis a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companys lead drug candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The company initiated a Phase 3 registrational study in DbCM inSeptember 2019.Applied Therapeuticsis also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease, and initiated a Phase 1/2 clinical trial inJune 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.

Forward-looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding(i) the design, scope and results of our clinical trials, (ii) the timing of the initiation and completion of our clinical trials, (iii) the likelihood that data from our clinical trials will support future development of our product candidates, (iv) the likelihood of obtaining regulatory approval of our product candidates and qualifying for any special designations, such as orphan drug designation, (v) our cash runway and the timing of our clinical development plan.Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the uncertainties inherent in the initiation, execution and completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions of regulatory agencies, in the commercialization and acceptance of new therapies. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with theU.S. Securities and Exchange Commission, including the Risk Factors contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Contacts

Investors:Maeve Conneighton(212) 600-1902 orappliedtherapeutics@argotpartners.com

Media:Brittany Horowitz(212) 704-4466 ormedia@appliedtherapeutics.com

Read the original:
Applied Therapeutics to Present Data Highlighting AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2019...

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets the Saphyr system, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced that leading organizations, including PerkinElmer Genomics and the University of Iowa, have adopted Saphyr for use in their clinical genomics laboratories. PerkinElmer Genomics and the University of Iowa have developed assays based on the Bionano optical mapping technology to expand their comprehensive suite of genetic tests assessing disease-associated chromosomal abnormalities. Their lead indication is Facioscapulohumeral Muscular Dystrophy (FSHD).

FSHD is one of the most prevalent forms of muscular dystrophy and affects approximately 1 in 10,000 individuals. It is caused by changes in the number of repeats in a section of chromosome 4. To correctly diagnose FSHD, an exact count of the repeat number is necessary. To date, molecular diagnoses for FSHD are generated using outdated Southern Blot techniques, which are imprecise, labor intensive and involve radioactive labeling methods which are being phased out of laboratory use for safety reasons. In contrast, the assays developed by PerkinElmer Genomics and the University of Iowawith the Bionano EnFocus FSHD Analysis tool are reproducible, safe, fast, and automated with minimal hands-on time. These assays provide an exact repeat number for the pathogenic and non-pathogenic variants, give a high-resolution view of the repeat regions and have a high sensitivity to mosaicism.

Jamshid Arjomand, Ph.D., CSO of the FSHD Society, the leading research-focused patient organization forFSHD, said, The FSHD community has been waiting years for an accessible and robust assay like this. The lack of timely and affordable genetic testing has been a major hurdle for the FSHD community. Thousands of patients have never received a molecular diagnosis, which limits successful recruitment into the increasing number of clinical research and clinical trial studies for this devastating disease. We are delighted that Bionanos Saphyr system enables a more precise and higher throughput method for FSHD genetic testing and are grateful to diagnostic groups and companies that are making genetic testing more accessible to our families.

We are pleased to be the first US laboratory to develop and validate an assay based on the Bionano Saphyr system in a clinical setting under CLIA/CAP guidelines" stated Madhuri Hegde, Ph.D., FACMG, Vice President and CSO of PerkinElmer Genomics. "We are committed to helping patients and families that need genetic testing and are excited about the strong clinical utility of this assay for the molecular assessment of FSHD patients."

Erik Holmlin, Ph.D., CEO of Bionano, commented, We have always believed that Bionanos unique ability to image long, intact DNA molecules could enable the Saphyr system users to develop assays in a clinical setting to modernize and streamline the practice of cytogenetics. Our teams have worked tirelessly to improve the speed, quality, throughput, and robustness of the optical mapping application of genome imaging while simultaneously reducing cost, assay complexity and data analysis. We believe Saphyr is ready to be adopted for assay development in a routine clinical workflow, and we are thrilled that PerkinElmer Genomics and the University of Iowa are taking the lead in making the Saphyr system a tool for next-generation cytogenomics, with many other academic, CRO and reference laboratories expected to follow. We believe that FSHD is just the start of a wide array of clinical genetics assays that labs will develop with our technology.

Results of the PerkinElmer Genomics FSHD evaluation study using the Saphyr system will be presented by Alka Chaubey, Ph.D., FACMG, Head of Cytogenomics and Laboratory Director at PerkinElmer Genomics at the Bionano Genomics ASHG exhibitor workshop on Thursday, Oct. 17, 2019 from 12:45 pm 2:00 pm at the Houston Marriott Marquis. More information about the workshop can be found online, and a recording will be made available on Bionanos website.

Bionano will showcase the Bionano EnFocus FSHD Analysis tool for fast, streamlinedbioinformaticsassessment of theFSHD locusfrom genome-wide optical mapping data at booth #527 during the annualAmerican Society of Human Genetics Annual Meeting, Oct. 15-19, 2019.

About Bionano Genomics

Bionano is a life sciences instrumentation company in the genome analysis space. Bionano develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets andto establish digital cytogenetics, which is designed to be a more systematic, streamlined and industrialized form of traditional cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools. More information about Bionano Genomics is available at http://www.bionanogenomics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, including, among other things: conclusions as to Saphyrs potential as a powerful new tool in cytogenetics; Saphyrs potential contribution to improvements in traditional cytogenetics; the University of Iowas or PerkinElmer Genomics plans to develop additional assays using our technology; our beliefs regarding the Saphyr systems readiness for clinical adoption andour expectations regarding adoption by other academic, CRO and reference laboratories using our technology; PerkinElmer Genomics commercial plans; plans of other Saphyr system users to implement their own assays for FSHD and other genetic disorders; and certain planned presentations by PerkinElmer Genomics and us. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks that our sales, revenue, expense and other financial guidance may not be as expected, as well as risks and uncertainties associated with general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of key clinical studies to demonstrate the effectiveness of our products; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2018 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Contacts

Company Contact:Mike Ward, CFOBionano Genomics, Inc.+1 (858) 888-7600mward@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617)775-5956arr@lifesciadvisors.com

Media Contact:Kirsten ThomasThe Ruth Group+1 (508) 280-6592kthomas@theruthgroup.com

Go here to see the original:
Bionano Genomics Announces Adoption of Its Saphyr System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for...

Stefan Mundlos, from the Max Planck Institute for Molecular Genetics, explains why there will be no designer babies in the near future

The first genetically modified humans were born in China in 2018. Now scientists and politicians in Russia are discussing whether using CRISPR/Cas9 to edit the genome of human embryos should be permitted. Stefan Mundlos, of the Max Planck Institute for Molecular Genetics in Berlin, is a member of the Genome Editing working group within the Ethics Council of the Max-Planck-Gesellschaft. The scientist, who himself uses CRISPR/Cas in his research, believes the concern over uncontrolled manipulation of the human genome is exaggerated.

Stefan Mundlos conducts research into rare bone diseases triggered by altered genes.

Edgar Zippel

Professor Mundlos, is the modification of human cells ethically justifiable?

It depends whether we are talking about normal body cells the somatic cells as they are known or about germline cells: sperm and egg cells. Somatic cells do not pass on their genetic material. If the genome of these cells is modified, the mutation disappears with the death of the patient. Such an intervention for the treatment of hereditary conditions or cancer is comparable to other cell-based therapies and therefore ethically unproblematic.

What about germline genome editing?

Thats completely different. The task of sperm and egg cells is to provide offspring. So they pass on their genetic material to the next generation. Manipulating the germline will therefore affect people who are not yet born at the time of modification, and cannot therefore give their consent. Thats ethically unacceptable. As genome editing is also not yet precise enough to avoid causing unintended mutations, the Max-Planck-Gesellschaft has spoken out against interventions in the germline in its discussion paper on genome editing.

How safe is the technique then?

CRISPR/Cas9 does work very precisely, and almost always cuts the DNA at a defined point. But despite that, mistakes can happen. Researchers are currently working on even more exact and less error-prone variations of the technique. In any case, we will always have to check whether modified cells do indeed only carry the desired mutations.

What significance will genome editing in humans have in the future?

The modification of normal body cells definitely has great medical potential. Conditions that are caused by one or a few mutations, such as some forms of leukaemia, could be treated this way. Im sure that well be able to treat the first patients using this method in just a few years.

On the other hand, I dont see any need for germline gene therapy, since there are equivalent and ethically less problematic alternatives. Using in-vitro fertilization and pre-implantation diagnostics, embryos free from adverse mutations can be selected for implantation.

Many people fear that genome editing will be used not just for treating illnesses, but also to optimize human characteristics. In the future, will we have particularly intelligent or tall designer babies thanks to this new technique?

I dont see any danger of this happening in the foreseeable future. Characteristics such as intelligence, height, or other characteristics we might wish to optimize, are influenced by many different genes. We are far from even understanding these gene networks, much less being able to manipulate them. Its quite possible that doing this will be completely impossible without triggering undesired effects elsewhere.

Some scientists are demanding a moratorium, a voluntary commitment to refrain from carrying out any modification of the human germline. What do you think about that?

I dont believe such a moratorium would be effective. The circle of scientists who can implement the technology is too wide for that. There will always be someone, somewhere in the world, who doesnt feel bound by the moratorium. And in any case, who would be responsible for policing it?

Is there no stopping the manipulation of the human genome then?

Im convinced that the lack of benefit will be much more effective than bans or voluntary commitments regarding germline gene therapy. Why would a pregnant woman have egg cells removed, if she can achieve the same result for her child by much less troublesome means? There would be no reason, and therefore no market for it.

Excerpt from:
"There is no reason for germline therapy" - Mirage News